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Despite considerable efforts during the last two decades, all
attempts to develop an effective human immunodeﬁciency virus
(HIV) vaccine that prevents infection or signiﬁcantly delays the
progression to AIDS have failed (Flynn et al., 2005; Gilbert et al., 2005a;
Gilbert et al., 2005b; Steinbrook, 2007). Difﬁculties lie in properties
speciﬁc to HIV such as the particularly high sequence diversity in
circulating isolates worldwide (Korber et al., 2001), the targeting of
critical immune cells (Mehandru et al., 2004; Steinbrook, 2007) or the
multiple strategies evolved by the virus to avoid immune elimination
(Le Gall et al., 1998; Wyatt and Sodroski, 1998; Yang et al., 2002). The
most promising strategy for preventing HIV-1 infection would be a
vaccine that induces broadly neutralizing antibodies before infection
(Barouch, 2008;Walker and Burton, 2008). Indeed, passive infusion of
broadly cross-reactive neutralizing antibodies in animal models
effectively confers protection against challenge infection (Baba et al.,
2000; Ferrantelli et al., 2004; Hessell et al., 2009a; Hessell et al., 2009b;Mascola et al., 1999;Mascola et al., 2000; Shibata et al., 1997). Vaccine-
mediated protection from AIDS virus infection has only been achieved
in primate models, using live-attenuated simian immunodeﬁciency
virus (SIV) vaccines carrying major deletions in nef and/or other
accessory genes (Almond et al., 1995; Daniel et al., 1992;Wyand et al.,
1999; Wyand et al., 1996). Unfortunately, safety concerns have
hampered the development of attenuated vaccines. Some animals
infected with nef-deleted SIV progressed to AIDS in the absence of
wild-type challenge (Hofmann-Lehmann et al., 2003; Sawai et al.,
2000). In addition, of the few described long-term nonprogressors
(LTNP) naturally infected with nef-defective strains (Kirchhoff et al.,
1995; Learmont et al., 1999), some showedCD4+T-cell loss aftermany
years of asymptomatic infection (Birch et al., 2001; Churchill et al.,
2004; Churchill et al., 2006; Gorry et al., 2007; Learmont et al., 1999).
Nevertheless, considerable effort has been made to understand the
factors that promote protection against disease progression in such
patients, to gain insight into protective immune responses, and thus
pave the way for a protective HIV vaccine (Dyer et al., 1999;
Greenough et al., 1994; Verity et al., 2007).
The LTNP status is not necessarily due to HIV infection with a
defective virus. Host factors, such as the expression of protective human
leukocyte antigen (HLA) alleles, also appear to play an important role in
the control of viremia in some LTNPs infected by fully replicative HIV-1
strains (Kaslow et al., 1996; Kiepiela et al., 2004; Lambotte et al., 2005).
Major histocompatibility complex class I alleles, such as HLA-B57,
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disease progression. Recent studies have shown that, in subjects
expressing these alleles, the control of HIV-1 replication is linked to an
HIV-1-speciﬁc CD8+ T-cell response directed, early in infection, against
a highly conserved regionwithin p24 Gag (Almeida et al., 2007; Streeck
et al., 2007). A nonprogressive clinical course in HLA-B57 and -B5801
HIV-infected individuals has also been shown to be associated with a
preserved CD8+ T-lymphocyte response to the HW9 epitope in Nef
(Navis et al., 2008).
Here, we report an informative case of superinfection in a LTNP
initially infected with a nef-defective HIV-1 strain. Both initial and
superinfecting viruses belonged to subtype B. Superinfection led to
increased viral replication and progressive loss of CD4+ T cells, despite
the expression of the protective HLA-B57 allele by this patient. Our data
showed the limited capacity of a natural infection with a putatively
attenuated HIV-1 strain to generate protective immune responses, both
in terms of induction of neutralizing antibodies and the generation and
preservation of speciﬁc cytotoxic T-lymphocyte responses.
Results
Loss of control of HIV-1 infection of patient 4050
Patient 4050, a 58-year-old homosexual male, was included in the
French “Asymptomatiques à Long Terme” cohort (ANRS CO15) in June
1995, after 10 years of seropositivity and 5 years of stable CD4+ T-cell
countN600 cells/mm3. He had no clinical symptoms and had not
received antiretroviral therapy, thus fulﬁlling the LTNP criteria. On
inclusion in the cohort, he had extremely low viral loads, i.e., a plasma
HIV-1 RNA level of 135 copies/ml and a cellular HIV-1 DNA level of 28
copies/106 PBMCs. However, after this long period of stability, plasma
viremia increased progressively, reaching 10,350 copies/ml in March
1999 (month 45 following T1, the time of patient inclusion), with a
concomitant progressive decline in the CD4+ T-cell count to below 600
cells/mm3 after January 1999 (Fig. 1). Patient 4050 initiated antire-
troviral treatment in March 1999, a period when HAART was initiated
earlier than the current consensus, leading to the rapid control of viral
replication and an increase of CD4+ T-cell numbers.
Patient 4050 was infected initially by a nef-defective HIV-1 virus
We previously described sequences of the V1-to-V5 region of the
env gene obtained from the proviral DNA extracted from PBMCs of
patient 4050, collected on inclusion in the cohort (Braibant et al.,Fig. 1. Course of infection in patient 4050 over the 5 years after inclusion in the LTNP
cohort. Plasma viral loads and CD4+ T cell counts are indicated by open diamonds and
closed squares, respectively. Time points at which blood samples were collected are
indicated by arrows (T1, T2, and T3 : time at enrollment and 1 and 2 years later,
respectively). The time at which treatment was initiated is indicated (HAART).2008). In this previous study, analyses of 15 different clones revealed
a high proportion of defective clones (14 of 15 clones, i.e., 93%) with
nucleotide deletions leading to frameshifts and premature stop
codons in the env gene (Braibant et al., 2008). We hypothesized
that the LTNP status of patient 4050, whose cells accumulated
proviruses defective in the env gene, may be associated with infection
by an HIV-1 isolate harboring deﬁcient accessory proteins Vif or Nef,
as reported by others (Calugi et al., 2006; Pace et al., 2006). We
therefore ampliﬁed the complete vif and nef genes by nested PCRs and
cloned the PCR products into the pCR2.1 vector. A total of 28 nef clones
and 30 vif clones present on inclusion were obtained and sequenced.
Sequences analysis of vif clones, using HIV-1 NL4.3 as the reference
sequence, did not show signiﬁcant mutations (data not shown). In
contrast, a major genetic change was found in nef sequences. All
sequences contained a deletion of 20 nucleotides (between nucleo-
tides 224 and 243 of the reference sequence), leading to a truncated
Nef protein (premature stop codon at position 261 to 263 of the
nucleotidic reference sequence) that lacked major functional motifs
(for reviews, see Foster and Garcia, 2008; Geyer et al., 2001). Nucleic
acid and amino acid consensus sequences derived from the quasis-
pecies population in patient 4050 are shown in Fig. 2.
Loss of viral control was associated with superinfection
The loss of control of HIV-1 infection of patient 4050 after more
than 10 years of stability in presence of a partially defective genome
raised the possibility that this change could be due to HIV-1
superinfection. To investigate this hypothesis, we compared env
(V1–V5 region), nef, vif, and gag (part of the P24 coding sequence)
sequences from PBMC samples collected at different time points. For
each gene, 22 to 30 clones were obtained and sequenced at entry into
the cohort (T1) and 2 years later (T3). In addition, for gag and nef
genes only, 22 to 24 clones were obtained and sequenced at an
intermediate time point, i.e., 1 year after entry into the cohort (T2).
Phylogenetic analyses of env, nef, vif, and, to a lesser extent, gag
sequences clearly suggested the sequential infection of patient 4050
by two phylogenetically distinct subtype B strains (strains 1 and 2)
(Fig. 3). Vif, env, nef, and gag sequences were more similar to
equivalent sequences of subtype B reference strains than to those of
strains of other subtypes. All clones sequenced for nef, vif, and gag, and
most of those sequenced for env (22 of 25 clones), collected at T1,
clustered in the same branch but were phylogenetically distinct from
those recovered at T3, which clustered in another branch (Figs. 3A–D).
The genetic distances between the two HIV-1 strains (strains 1 and 2)
within the sequenced regions were 15.7%±1.3% in env, 4.0%±0.8% in
nef, 5.1%±0.9% in vif, and 2.9%±0.7% in gag. The large genetic
distance observed in env sequences provides further evidence of a
dual infection in patient 4050.
None of the env sequences recovered at T3 was genetically altered
(Fig. 3A). However, only three of those recovered at T1 were
genetically intact. Two of these genetically intact sequences were
more closely related to those recovered at T3, and the third, although
phylogenetically linked to sequences of strain 1, differed by a smaller
genetic distance from env sequences of strain 2 (9.5%±0.8% versus the
average genetic distance of 15.7%±1.3%) (Fig. 3A). The alignment of
this third nucleotide sequence of envwith the consensus sequences of
strain 1 and strain 2 suggested that a recombination event had
occurred between these two infecting strains. This ﬁnding was
conﬁrmed using the recombinant identiﬁcation program RIP 3.0
(Fig. 4). The recombination breakpoint was found in the C2 constant
region of the envelope glycoprotein, in a previously described hotspot
region corresponding to the top portion of an RNA hairpin structure
(Galetto et al., 2006; Galetto et al., 2004). These three genetically intact
sequences suggested that strain 2 was already present in subject 4050
at time of inclusion. However, the predominance of strain 2 after
2 years showed that it is likely to have a growth advantage over strain
Fig. 2. Alignment of nucleic acid and deduced amino acid nef sequences. A, Nucleic acid consensus sequence derived from the quasispecies population recovered from DNA extracted
from PBMCs of patient 4050, collected at time of inclusion in the cohort, is aligned with the nef sequence of the NL4.3 reference strain. Identical and absent nucleotides are
represented by dots and dashes, respectively. The observed 20 nucleotides deletion and the resulting premature stop codon are highlighted in gray. B, Amino acid consensus
sequence is aligned with NL4.3 Nef sequence. Identical and absent nucleotides are represented by dots and dashes, respectively. Known Nef functional motifs/regions are indicated.
Regions playing a role in CD4 andMHC-1 down-regulation are indicated by CD4↓ andMHC-1↓. These regions include motifs involved in the internalization and trafﬁcking of Nef [i.e.,
a WL motif interacting with the cytoplasmic tail of CD4, an acidic cluster of four glutamic acids (EEEE) interacting with PACS-1, a highly exposed cluster of three amino acids (FDP)
interacting with the human thioesterase, a di-glutamic acid (EE) motif interacting with β-COP in endosomes, a di-leucine (LL) motif interacting with adaptor complexes AP-1 and
AP-2, and a di-aspartic acid motif (DD) interacting with the subunit H of the vacuolar ATPase (V1H)], motifs involved in cellular activation and signaling by Nef [i.e., a proline-rich
motif (PxxPxxPxRP) interacting with the SH3 domains of Src family kinases and two arginine residues (RR) interacting with members of the p21-activated kinase (Pak) family] and
one motif involved in Nef modiﬁcation [the N-myristoylation site (MGxxxS/T)].
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entry into the cohort.
All nef sequences determined at T1 (strain 1) were defective and
phylogenetically distinct from those recovered at T3, which were not
altered (strain 2) (Fig. 3B). Twenty sequences recovered at T2
clustered with strain 1 and two clustered with strain 2. However, in
contrast to strain 1 sequences,most T2 sequences (18 of 20) clustering
with strain 1 were not altered. The alignments indicated that they
resulted from a recombination between the two infecting strains, as
shown using the recombinant identiﬁcation program RIP 3.0 (Fig. 5).The majority of vif and gag sequences were not altered, whether
from strain 1 or strain 2 (Fig. 3C). The sequenced region of gag was
chosen as it contained the most common CTL HLA-B57-restricted
epitopes. However, this regionwas short (448 nucleotides) and highly
conserved, even among different strains of subtype B. Thus, the
clustering of sequences, and whether they belonged to a single
evolving strain or to two different strains, was not so clear (Fig. 3D).
Nevertheless, sequences recovered at T1 were phylogenetically
distinct from those at T3 and, although the genetic distances between
the two populations and the bootstrap values were smaller than for
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two different strains (strain 1 and strain 2) (Fig. 3D). Almost all the
sequences recovered at T2 (23 of 24), although forming a cluster
distinct from the T1 sequence cluster, were more closely related to T1
than to T3 sequences (average genetic distances of 1.6%±0.05%
for sequences found at T1 versus 2.7%±0.07% for those found at T3).
We therefore speculated that they belong to the same initial strain
(strain 1) and resulted from a series of genetic changes in this strain,
over the course of one year. By contrast, one sequence recovered at T2
clustered with sequences recovered at T3, and was therefore probably
derived from strain 2.
Absence of heterologous neutralizing antibody responses
We previously assessed the ability of plasma from patient 4050,
collected at time of inclusion in the cohort, to neutralize a panel of
four heterologous primary isolates belonging to four different clades
or circulating recombinant forms (B, F, CRF01-AE, CRF02-AG)
(Braibant et al., 2008). Plasma from patient 4050 did not display
neutralizing activity against any of the four strains tested, even at the
lower plasma dilution used. We carried out more speciﬁc tests to
determine whether plasma from patient 4050 contained neutralizing
antibodies against the superinfecting virus on entry into the cohort.
We thus studied the capacity to neutralize pseudoviruses expressing
functional envelope proteins generated using ﬁve env sequences
recovered from the superinfecting virus, i.e., 1 of the 2 cloned
sequences (CL6) recovered at time of entry into the cohort and 4 of
the 22 sequences (CL1 to CL4) obtained 2 years later (Fig. 3A). The
neutralization proﬁles for each of the ﬁve pseudoviruses were very
similar. Neutralization levels were very low, failing to reach 90%
neutralization even using a 1:20 dilution of plasma, the highest
plasma concentration tested (Fig. 6). The calculated IC50 values
(deﬁned as the reciprocal of the plasma dilution resulting in 50%
neutralization) were very low, ranging from 125 to 167. We further
evaluated the presence of neutralizing antibodies in this patient's
plasma by testing the ability to neutralize pseudoviruses expressing
the env sequence cloned from the laboratory adapted strain NL4-3 of
subtype B, which is known to be sensitive to neutralization.
Neutralization of these pseudoviruses reached 90% using the two
highest concentrations (1:20 and 1:60) (Fig. 6). Calculated IC90 and
IC50 values were 167 and 941, respectively.
Time course of CD8+ cellular immune responses
To address the importance of HIV-speciﬁc CTL responses generated
by infection with the nef-defective strain and subsequently by the
superinfecting strain, we tested PBMCs collected at T1, T2, and T3 for
responses against pools of various synthetic 15-mer peptides, using an
IFN-γ-ELISpot assay. These peptides spanned the entire HIV-1-Gag
(three p17 pools, ﬁve p24 pools, and three PP pools), HIV-1-RT (four
pools), and HIV-1-Nef (three pools) sequences of HxB2. At T1, when
the initial nef-defective HIV-1 strain predominated, only two p24
peptide pools were recognized by CD8+ T cells (p24 pools 1 and 3;
350 and 325 SFC/106 PBMCs, respectively) (Figs. 7A–C). At T2, when
the superinfecting virus was present but not yet predominant, CTL
responses increased. A total of nine peptides pools, including one pool
of p17, four pools of p24, one pool of PP, one pool of RT, and two pools
of Nef, were recognized by CD8+ T cells. Again, the two mainly
recognized pools were p24 peptide pools 1 and 3 (777 and 550 SFC/
106 PBMCs, respectively) and, to a lesser extent, p24 peptide pool 4
(210 SFC/106 PBMCs), and Nef peptide pool 3 (310 SFC/106 PBMCs).Fig. 3. Phylogenetic analysis of env (A), nef (B), vif (C), and gag (D) sequences obtained from
(T2, gray diamonds) and 2 years after inclusion (T3, open circles). A distance scale is given
replicates; only values above 60% are indicated on nodes. Reference sequences of various sub
nucleotide accession number. Defective sequences are indicated by asterisks.At T3, when the superinfecting virus predominated, the CTL responses
were weaker and were similar to those detected at T1 (p24 pools 1
and 3; 297 and 270 SFC/106 PBMCs, respectively).
The two most frequently recognized p24 pools (pools 1 and 3)
cover amino acids (aa) 133 to 187 and 221 to 275 of Gag, respectively,
and therefore include the HLA-B57-restricted IW9, KF11 and TW10
epitopes. The Nef peptide pool 3 covers aa 97 to 147 and includes the
HLA-B57-restricted HW9 epitope. To determine whether the ob-
served responses were targeted to these HLA-B57-restricted epitopes,
peptides corresponding to these epitopes were tested individually. In
addition, one peptide corresponding to the HLA-B57-restricted YY9
Nef epitope (not included in any used Nef peptide pools) was also
tested. Due to the lack of PBMCs collected at T3, this was carried out at
two time points only (T1 and T2).
For Gag, the two main targeted epitopes were indeed IW9 (230 and
895 SFC/106 PBMCs at T1 and T2, respectively) and KF11 (405 and 540
SFC/106 PBMCs at T1 andT2, respectively). By contrast, the TW10epitope,
the early and immunodominant targeting ofwhich has been correlated to
the nonprogression of HIV-1 infection inHLA-B57 individuals, gave rise to
more moderate responses (105 and 240 SFC/106 PBMCs at T1 and T2,
respectively). Analysis of Gag viral sequences revealed the presence of a
previously describedTW10CTL escapemutation (T242N) in all sequences
recovered fromthe superinfecting strain, i.e., all sequences recoveredat T3
and the single related sequence recovered at T2 (Figs. 3D, 7, and 8D).
Analysis of CTL responses to the mutated epitope TW10mut revealed a
weaker response to the mutated epitope at T2 (155 and 240 SFC/106
PBMCs for TW10mut and TW10 wild type, respectively), suggesting that
the lowCTL response to this keyepitopemayhave impaired theearly viral
containment of the superinfecting strain.
For Nef, neither wild-type HW9 nor wild-type YY9 was recognized
at any time. Analysis of viral sequences showed one mutation in HW9
(HW9mut F121L) in 3 of the 22 sequences recovered at T2 and in all 25
nondefective sequences recovered at T3 and one mutation in YY9
(YY9mut1 Y135F) in all sequences recovered at T2 and T3 (Figs. 3B, 5,
and 8D). An additional mutation in YY9 (YY9mut2 I133T)was observed
for most of the sequences recovered at T2 but was no longer observed
at T3. No CTL responses against these mutants were observed except a
weak response against HW9mut at T2 (105 SFC/106 PBMCs).
Discussion
We describe an HLA-B57-positive LTNP (patient 4050), in whom
we previously showed that PBMCs accumulated HIV-1 subtype B
proviruses with a defective env gene (Braibant et al., 2008). However,
after more than 10 years of control of infection, plasma viremia
increased progressively, with a concomitant progressive loss of CD4+
T cells. Here, the data suggest that this patient was initially infected by
a nef-defective HIV-1 variant and that loss of control was due to
superinfection with a fully competent virus belonging to the same
clade B. Although we could not precisely determine the time of
superinfection due to the lack of available samples before enrollment,
the recovery at T1 (at entry in the cohort, after N10 years of infection)
of two env sequences related to those of the superinfecting strain
suggested that this patient was already superinfected at that time.
However, the few env sequences recovered and the complete absence
of nef, gag, and vif sequences belonging to the superinfecting strain at
T1 suggested that superinfection occurred at or not long before T1,
and at least probably not around the time of primary infection. This
assumption is strengthened by the extremely low cellular viral load
accumulated at T1 (28 copies/106 PBMCs), in accordance with
infection by a poorly replicative HIV-1 strain.PBMC samples collected at time of inclusion (T1, closed triangles), 1 year after inclusion
for each neighbor-joining tree. Bootstrap values are expressed as percentages per 500
types are included in each tree. Each of these sequences is indicated by its subtype and
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previously reported in an LTNP infected with nef-deﬁcient virus
(Calugi et al., 2006). A similar observation made in our patient might
suggest that nef and env deletions might be linked. As previously hy-
pothesized, it seems likely that, in the absence of down-regulation
of class 1 major histocompatibility complex molecules by Nef, CD8+
cytolysis is more efﬁcient in eliminating cells presenting wild-type Env,
whereas cells with truncated Env accumulate (Calugi et al., 2006).
Althoughwedid not analyze the functional properties of theNef protein
in the nef-defective HIV-1 variant infecting our patient, we can predict
that, expressed or not, its truncated form lackingmajor domains would
not be functional. The 20 nucleotides deletion observed in nef clones did
not contain any B57-restricted epitopes and therefore could not be a
response to a selective pressure from CTL responses.
Superinfection of patient 4050 showed that the nef-deﬁcient HIV-1
strain was unable to induce immune responses that protect against
HIV-1 superinfection or that control the new virus after superinfec-
tion. This raised the question of the extent of neutralizing antibodies
and/or CTL responses generated by such a putatively attenuated HIV-
1 strain. A number of studies have shown that broadly neutralizing
antibody responses are more frequent in LTNP than in other HIV-1-
infected patients (Cao et al., 1995; Carotenuto et al., 1998; Cecilia et
al., 1999; Pilgrim et al., 1997). However, none of these studies ad-
dressed the question taking into account the properties of the genes—
intact or delete—of the infecting viruses. Several reports have shown
that nef-deleted SIV may induce neutralizing antibodies in macaques
(Cranage et al., 1997; Enose et al., 2002; Kumar et al., 2002; Monteﬁori
et al., 1996; Stipp et al., 2000). A recent study of the antibody
responses in eight blood transfusion recipients infected with a nef-
attenuated HIV-1 acquired from a single donor (Sydney Blood Bank
Cohort) showed a strong association of broader neutralizing antibody
responses with higher viral load and a higher risk of disease
progression (Verity et al., 2007). This highlights the importance of
viral replication in mounting a robust humoral immune response, as
we observed in a previous study (Braibant et al., 2006). Three LTNPs in
this cohort, who had remained asymptomatic with undetectable
plasma viral load and stable CD4+ T-cell counts since 1993, had little
or no neutralizing activity in their sera. In the case of patient 4050 in
this study, we found that, at the time of superinfection, his plasma did
not contain neutralizing antibodies against four heterologous primary
isolates, including one subtype B strain (Braibant et al., 2008), but
neutralized the neutralization-sensitive NL4-3 strain. Using an Env-
pseudotyped virus neutralization assay, we also showed that the
patient's serum did not contain antibodies able to efﬁciently
neutralize the superinfecting virus. Although we cannot be sure that
the presence of heterologous neutralizing antibodies would have been
efﬁcient in preventing superinfection if they had been present, it
seems likely that the risk of superinfection was increased by the lack
of such antibodies. The control of HIV-1 in HLA-B57 patients has been
attributed to an early and immunodominant CTL response targeting a
highly conserved Gag epitope, TW10 (Streeck et al., 2007). In patient
4050, dominant responses were observed at T1 and one year after
superinfection and were directed mainly toward two epitopes in Gag,
IW9 and KF11, but more moderately toward TW10. The two major
targeted epitopes, IW9 and KF11, were conserved in the uncontrolled
superinfecting virus suggesting that these speciﬁc CTL responses were
inefﬁcient at controlling infection by a fully competent virus.
However, we cannot exclude the possibility that these responsesFig. 4. Recombination between strain 1 and strain 2 in env sequences. A, Recombinant nuc
Identical and absent nucleotides are represented by dots and dashes, respectively. When
represented by uppercase letters if conserved in 100% of sequences and by lowercase if cons
region presumed to contain the recombination breakpoint is outlined by a box. B, Graph ge
trace the similarity between the recombinant env sequence and the consensus strain 1 and
center of a window (size of 200) moving in increments of one nucleotide residue from left t
sequence. The upper horizontal colored line shows whether the best match is signiﬁcantlycontributed to the control of the nef-defective variant expressing
higher levels of major histocompatibility class I (MHC-I) molecules.
The down-regulation of MHC-I molecules by Nef is a highly
documented potential mechanism developed by the virus to blunt
cytotoxic T-cell recognition of infected cells (Malim and Emerman,
2008). In addition, the diversity of functional properties assigned to
Nef, i.e. CD4 down-regulation, enhancement of virion infectivity,
T-cell receptor (TCR-CD3) regulation (Malim and Emerman, 2008),
might have contributed to the control of the replication of the nef-
deleted virus.
In contrast, the superinfecting virus had a T242N mutation in the
TW10 epitope, previously described as an escape mutation from
HLA-B57 restricted cytotoxic T cells that causes a ﬁtness cost for the
virus (Martinez-Picado et al., 2006). The even lower CTL response to
this mutated epitope compared to that toward the wild type TW10
epitope may suggest that the occurrence of this mutation contributed
to the lack of control of the incoming virus. Nevertheless, as we did
not determine the sequence of the donor virus, we cannot exclude the
presence of this mutation already at the time of transmission. Despite
the previously described ﬁtness cost for the virus, we showed here in
patient 4050 that the virus carrying this mutationwas associated with
a progressive disease course. This could be attributed to compensa-
tory mutation(s) that restore the replication capacity of the mutant.
However, none of the previously described upstream mutations in
Gag shown to partially restore replication of the T242N variant were
found in sequenced Gag clones of the superinfecting virus (Brockman
et al., 2007; Kirchhoff et al., 1995; Martinez-Picado et al., 2006). In
summary, although a speciﬁc CTL response against Gag was present in
the patient at T1, including two HLA-B57-restricted epitopes, this
response was not sufﬁcient to control the superinfection. No Nef-
speciﬁc CTL response was present at T1, an observation that seems
logical due to exposure only to the Nef-deﬁcient virus at that time.
The reported case brings additional elements suggesting that the
presence of weak neutralizing antibodies and/or speciﬁc CTL
responses are inefﬁcient for elimination of the virus or a successful
containment preventing the development of the disease when
naturally exposed to a fully competent HIV strain. This highlights
the considerable difﬁculties that remain to generate immunogens able
to inducemore potent immune responses than those observed in HIV-
1-infected patients with long-lasting infection.
Conclusions
Overall, our study suggests the limited capacity of even a long-
lasting natural infection with a putatively attenuated nef-deﬁcient
HIV-1 strain to elicit potent immune responses able to prevent and
control superinfection with a second virus of the same clade. Such
observations in this and other reports of superinfections (Altfeld et al.,
2002; Blish et al., 2008; Casado et al., 2007; Jost et al., 2002; Streeck
et al., 2008) highlight the considerable difﬁculties that need to be
overcome to develop a successful rational for a preventive vaccine.
Materials and methods
Study subject
Patient 4050 was recruited to the French “Asymptomatiques à Long
Terme” cohort (ALT ANRS CO15) in 1995. The ALT status was deﬁned asleic acid env sequence is aligned with consensus strain 1 and strain 2 env sequences.
different from the recombinant env sequence, consensus sequence nucleotides are
erved in more than 50% of sequences. Env variable regions are highlighted in gray. The
nerated using the Recombinant Identiﬁcation Program—RIP 3.0. Red and green curves
strain 2 sequences, respectively. Each plotted point represents the distance value at the
o right in the alignment. The lower horizontal colored bar represents the best matched
better than the second match.
Fig. 5. Recombination between strain 1 and strain 2 in nef sequences. A, Recombinant nucleic acid nef sequence is alignedwith consensus strain 1 and strain 2 nef sequences. Identical
and absent nucleotides are represented by dots and dashes, respectively. When different from the recombinant nef sequence, consensus sequence nucleotides are represented by
uppercase letters if conserved in 100% of sequences, and by lowercase if conserved in more than 50% of sequences. The presumed recombination breakpoints are shown in boxes.
Nucleotides encoding B57-restricted epitopes in recombinant and consensus strain 2 sequences are highlighted in grey. Amino acids deduced sequences are represented above and
below recombinant and consensus strain 2 sequences, respectively. B, Graph generated using the Recombinant Identiﬁcation Program -RIP 3.0. Red and green curves trace the
similarity between the recombinant nef sequence and the consensus strain 1 and strain 2 sequences, respectively. Each plotted point represents the distance value at the center of a
window (size of 100) moving in increments of one nucleotide residue from left to right in the alignment. The lower horizontal colored bar represents the best matched sequence. The
upper horizontal colored line shows whether the best match is signiﬁcantly better than the second match.
88 M. Braibant et al. / Virology 405 (2010) 81–92an asymptomatic HIV-1 infection for at least 8 yearswith stable CD4+ T-
cell countN600 cells/mm3 over the previous ﬁve years and no
antiretroviral therapy (Candotti et al., 1999; Magierowska et al., 1999;
Martinez et al., 2005; Ngo-Giang-Huong et al., 2001). Patient 4050 wasinfected with a subtype B virus. Plasma viral load and DNA viral load
were determined as previously described (Candotti et al., 1999;
Rouzioux et al., 2005). Blood samples were collected at each visit,
every year, as described in the follow-up protocol for this cohort.
Fig. 6. Absence of potent neutralizing antibodies against the superinfecting strain.
Neutralization activity in plasma from patient 4050 collected at time of entry into the
cohort was determined for viruses pseudotyped with functional envelope proteins
corresponding to the 5 env sequences from the superinfecting virus (CL1 to CL4 and
CL6) or with the envelope protein of the laboratory adapted strain NL4-3. Percentage of
neutralization is plotted as a function of serum dilution.
89M. Braibant et al. / Virology 405 (2010) 81–92Nucleic acid extraction, PCR, and cloning
Genomic DNA was extracted from about 5 million frozen PBMCs
collected at each time point, using the QIAamp DNA Blood Midi kit
(Qiagen). Separate nested PCRs were used to amplify four regions of the
HIV-1 genome, consisting of a 1.2-kb fragment of the env gene
encompassing most of the gp120 coding sequence (from upstream V1
to downstream V5, nt 5941 to 7216 in the HXB2 genome), the complete
nefgene (nt 8343 to 8714 in theHXB2genome), the complete vifgene(nt
4587 to 5165 in the HXB2 genome), and a fragment of the gag gene
encompassing part of the P24 coding sequence (nt 717 to 1165 in the
NL4.3 genome). Subtype B env-speciﬁc primers and conditions of env
ampliﬁcationwerepreviouslydescribed (Braibant et al., 2008). SubtypeBFig. 7. Alignment of consensus strain 1 and strain 2 gag sequences. Identical nucleotides are
are conserved in 100% of sequences; those in lowercase are conserved in more than 50% o
amino acids deduced sequences are represented above and below consensus strain 1 and s
sequence.nef-speciﬁc outer primerswere nefB-sext (5′-GCAGTAGCTGAGGGGACAG-
ATAGGGTTATAG-3′) andnefB-asext (5′- CTCCCAGTCCCGCCCAGGCCAC-3′),
and inner primers were nefB-sint (5′- GACAGGGCTTGGAAAGGG-
CTTTGCTATAA-3′) and nefB-asint (5′- TCAGCAGTTCTTGTAGTACTCC-
GGATGC-3′). Subtype B vif-speciﬁc outer primers were vifB-sext
(5′-AGATAATAGTGACATAAAAGTAGTRCCAAG-3′) and vifB-asext (5′-
AAGTATCCCCATAAGTTTCATAGATATRTTG-3′), and inner primers were
vifB-sint (5′- GTRCCAAGAAGAAAAGCAAAGATCATTAGRG-3′) and vifB-
asint (5′- CCTAAGCCATGGAGCCAAATCCTAGGAAART-3′). SubtypeB gag-
speciﬁc outer primers were gagB-sext (5′-CAAAAGTAAGAAAAARGCA-
CARC-3′) and gagB-asext (5′- CCAGAATGCTGGTAGGRCTRTA-3′), and
inner primers were gagB-sint (5′- GGTCAGCCAAAATTACCCHATA-3′)
and gagB-asint (5′- CATYCTTACTATTTTATTTAATCCYA-3′). Ampliﬁca-
tions were carried out with the Platinum PCR SuperMix High Fidelity
(Invitrogen) under the following cycling conditions: 5 min at 94 °C,
followed by 35 cycles of 30 s at 94 °C, 30 s at 55 °C for vif and nef or 30 s
at 50 °C for gag and 1 min at 68 °C, and a ﬁnal extension step of 7 min at
68 °C. A 5-µl aliquot of the products of the ﬁrst round of PCR was then
transferred to a new reaction mixture containing the inner primer pair,
and a second round of ampliﬁcation was performed under the same
cycling conditions. All PCR products were inserted into pCR2.1 (Topo TA
cloning kit; Invitrogen), according to the manufacturer's instructions.Sequence analysis
All pCR2.1 clones were sequenced according to the Dye Terminator
cycle sequencing protocol (Applied Biosystems, Foster City, Calif.).
Nucleotide sequences were assembled with the BioEdit package
(version 5.0.9) and aligned using Clustal W (Hall, 1999; Thompson et
al., 1994). Phylogenetic analysis and tree reconstructions were
performed by the neighbor-joining method, with MEGA version 3.1
(Kumar et al., 2004; Saitou and Nei, 1987). The distance matrix was
calculated with the two-parameter Kimura algorithm (transition-to-
transversion ratio of 2.0) (Kimura, 1980). Approximate conﬁdence
limits for individual branches were assigned by bootstrap resampling
with 500 replicates.represented by dots. Consensus sequence nucleotides represented by uppercase letters
f sequences. Nucleotides encoding B57-restricted epitopes are highlighted in grey and
train 2 sequences, respectively. Numbering is that of the complete gag HxB2 reference
Fig. 8. Time course for CD8+ cytotoxic T-lymphocytes responses. Total CD8+ T-cell responses speciﬁc for the Gag protein (A), the RT protein (B), and the Nef protein (C) were
assessed at three time points (T1, T2, and T3) in IFN-γ-ELISpot assays by stimulation with overlapping peptide pools (three p17 pools, ﬁve p24 pools, and three PP pools for Gag, four
pools for the RT and three pools for Nef). Sequences of known HLA-B57 restricted epitopes in Gag (IW9, KF11, and TW10) and Nef (HW9 and YY9) and of their mutated variants
(TW10mut, HW9mut, YY9mut1, and YY9mut2) observed in viral sequences recovered from patient 4050 are shown in panel D. The number of viral sequences corresponding to each of
these wild-type or mutated epitopes is shown. Peptide-speciﬁc CD8+ T-cell responses were tested individually for Gag and Nef epitopes (panels E and F, respectively) at two time
points (T1 and T2).
90 M. Braibant et al. / Virology 405 (2010) 81–92Subcloning of gp120 env gene clones into expression plasmid
The complete gp160 NL4-3 env gene was inserted into the EcoRI
site of the pCR2.1 vector.
Part of the env gene coding for most of the gp120 was digested out
of this construct using NdeI and MfeI (New England Biolabs) and
replaced by the corresponding gp120 sequences excised from the
pCR2.1 vector by digestion with the same enzymes. Chimeric env
genes were then cloned into the EcoRI site of the pCI expression vector
(Promega).
Env-pseudotyped virus neutralization assay
Env-pseudotyped viruses were generated by cotransfecting 3×106
293T cellswith 4 μg of each pCI-envplasmid and8 μg of pNL4.3.LUC.R-E-
(Connor et al., 1995), using FuGene-6 HD Transfection Reagent (Roche
Applied Biosciences). After titration, pseudotyped virus stocks were
diluted to obtain 1000 TCID50/ml in growth medium. Aliquots of 50 μl,
corresponding to 50 TCID50, were then incubated for 1 h at 37 °C with
50 μl of three-fold serial dilutions of heat-inactivated serum. The virus/serummixture was then used to infect 10,000 TZM-bl cells (Platt et al.,
1998; Wei et al., 2002) in the presence of 30 μg/ml DEAE-dextran.
Infection levels were determined after 48 h, using the Bright-Glo
luciferase assay (Promega) and a Centro LB 960 luminometer (Berthold
Technologies) to measure luciferase activity in cell lysates. The assay
was performed in duplicate and results were expressed asmean values.
Neutralizing antibody titers were deﬁned as the reciprocal of the serum
dilution required to reduce relative luminescence units (RLUs) by 50%.
CD8+ T-cell epitopes and IFN-γ-ELISpot assay
Synthetic 15-mer peptides, overlapping by 11 amino acids (Neosys-
tem, Strasbourg, France, kindly supplied by ANRS) and spanning the HIV-
HxB2Gag, RT, andNef sequences,were divided into 18pools: 3 p17pools,
5 p24 pools, 3 PP (i.e., p2/p7/p1/p6) pools, 4 RT pools, and 3 Nef pools.
Nine CD8+ T-cell epitopes corresponding to HIV- Gag or Nef protein
sequences were synthesized: ISPRTLNAW (Gag147–155, IW9), KAFSPE-
VIPMF (Gag162–172, KF11), TSTLQEQIGW (Gag240–249, TW10),
TSNLQEQIGW(TW10mut: T242N), HTQGYFPDW (Nef116–124, HW9),
HTQGYLPDW (HW9mut: F121L), YTPGPGIRY (Nef127–135, YY9),
91M. Braibant et al. / Virology 405 (2010) 81–92YTPGPGIRF (YY9mut1: Y135F), and YTPGPGTRF (YY9mut2: I133T, Y135F).
All peptides were more than 80% pure, according to HPLC proﬁles. The
IFN-γ-ELISpot assays were performed as previously described (Martinez
et al., 2005). PBMC samples (viability above 85%) were stimulated with
Gag, RT, and Nef peptide pools (2 μg/ml for each peptide) or individual
peptides for18hours. ThecontrolsweremediumaloneorPHA(0.5 μg/ml,
Abbott, Rungis, France). Spots were counted with an ELISpot reader
(Axioplan-2 imaging, Zeiss, Germany). Data were expressed as SFC/106
PBMCs and considered positive if above 50 SFC/106 PBMCs after
subtracting mean background.
Nucleotide sequence accession numbers
All sequences have been submitted to GenBank and assigned
accession numbersEF179866–EF179880 and GU457024–GU457261.
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